ANQUIL Tablet Ref.[27601] Active ingredients: Benperidol

Posology

Adults

0.25-1.5 mg/day in divided doses. Dosage is best initiated and adjusted under close clinical supervision as individual response to neuroleptic drugs is variable.

In determining dosage, consideration should be given to the patient’s age, severity of symptoms and previous response to other neuroleptic drugs.

Patients who are debilitated, or those with previously reported adverse reactions to neuroleptic drugs, may require less Anquil, and half the normal starting dose may be sufficient for therapeutic response.

In adolescents, a lower dose may be advisable.

Elderly

Half the normal starting dose may be sufficient for therapeutic response.

Paediatric population

Not recommended.

As with all medications the lowest effective dose should be used.

Method of administration

Oral.

Symptoms

In general, the manifestations of Anquil overdosage are an extension of its pharmacological action. In patients who have received daily doses of 160 mg, the most prominent side effects were extrapyramidal symptoms such as oculogyric crisis, salivation, muscle rigidity, akinesia and akathisia. Drowsiness or paradoxical excitement may occur.

Treatment

There is no specific antidote to Anquil. Treatment consists of supportive and symptomatic measures combined with standard measures to remove any unabsorbed drug. Extrapyramidal symptoms should be treated with anti-Parkinson drugs as required.

60 months.

Protect from light.

The tablets are supplied in blister packs, containing 100 or 112 tablets.

Not all pack sizes may be marketed.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.